Dysregulation of Small Nucleolar RNAs in B-Cell Malignancies

Verbeek, Martijn W. C.; Erkeland, Stefan J.; Velden, Vincent H.J. van der

doi:10.3390/biomedicines10061229

Cited by 6 publications

(6 citation statements)

References 119 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SnoRNAs, a homogeneous group of non-coding RNAs that guide modifications of ribosomal RNA, have emerged as important players contributors in cancer. 57 , 58 Unlike microRNAs and lncRNAs, they possess distinct characteristics. Numerous studies have demonstrated that snoRNAs can be utilized as diagnostic and prognostic biomarkers in cancer.…”

Section: Discussionmentioning

confidence: 99%

Small Nucleolar RNAs as Diagnostic and Prognostic Biomarkers in Cancer: A Systematic Review and Meta-Analysis

Gao,

Fan,

et al. 2024

Technol Cancer Res Treat

View full text Add to dashboard Cite

Objectives Small nucleolar RNAs (snoRNAs) form clusters within the genome, representing a mysterious category of small non-coding RNAs. Research has demonstrated that aberrant snoRNAs can contribute to the development of various types of cancers. Recent studies have identified snoRNAs as potentially valuable biomarkers for the diagnosis or/and prognosis of cancers. However, there has been a lack of comprehensive reviews on prognostic and diagnostic snoRNAs across different types of cancers. Methods We conducted a systematic search of various databases including Google Scholar, Medline, Cochrane, Scopus, PubMed, Embase, ScienceDirect, Ovid-Medline, Chinese National Knowledge Infrastructure, WanFang, and SinoMed with a time frame reception to December 30, 2022. A total of 49 relevant articles were included in our analysis, consisting of 21 articles focusing on diagnostic aspects and 41 articles focusing on prognostic aspects. Pooled odds ratio, 95% confidence intervals (CIs), and hazard ratio (HR) were utilized to evaluate clinical parameters and overall survival (OS), respectively. Result The findings indicated that area under the curve, sensitivity, and specificity were 0.85, 75%, and 80% in cancer, respectively. There was a possibility that snoRNAs had a positive impact on the diagnosis (risk ratio, RR = 2.95, 95% CI: 2.75-3.16, P = 0.000) and OS (HR = 1) in cancer. Additionally, abnormally expressed snoRNAs were associated with a positive impact on OS time for chronic lymphocytic leukemia (HR: 0.88, 95%Cl: 0.69-1.11, P < 0.00001), colon adenocarcinoma (HR: 0.97, 95%Cl: 0.91-1.03, P < 0.0001), and ovarian cancer (HR: 0.98, 95%Cl: 0.98-0.99, P < 0.00001). However, dysregulated snoRNAs of colon cancer and colorectal cancer had a negative impact on OS time (HR = 3.01 and 1.01 respectively, P < 0.0001). Conclusion The results strongly suggested that snoRNAs could serve as potential novel indicators for prognosis and diagnosis in cancers. This systematic review followed the guidelines of the Transparent Reporting of Systematic Review and Meta-Analyses (PROSPERO register: CRD42020209096).

show abstract

Section: Discussionmentioning

confidence: 99%

Small Nucleolar RNAs as Diagnostic and Prognostic Biomarkers in Cancer: A Systematic Review and Meta-Analysis

Gao,

Fan,

et al. 2024

Technol Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Compared to Germinal center, naïve, marginal zone and memory B-cells, peripheral blood B cells express a distinct snoRNA pattern with reduced SNORD116-1, SNORD116-23, SNORD116-29, SNORD94, and SNORA36A expression ( 76 ), indicating these snoRNAs may play a key role in B cell maturation and function. SnoRNAs derived from the DLK-DIO3 locus(containing 41 snoRNAs) were reduced whereas the expression of SNURF/SNRPN snoRNAs remained high in different types of B-cell malignancies compared to healthy B-cells ( 77 ). SNORA25 was reported to target 18S rRNA subunit (18S-801 and 18S:U814) and mediate the pseudouridylation of these residues ( 78 ).…”

Section: Snorna-mediated Immune Cell Function To Participate In Tumor...mentioning

confidence: 99%

SnoRNA and lncSNHG: Advances of nucleolar small RNA host gene transcripts in anti-tumor immunity

et al. 2023

View full text Add to dashboard Cite

The small nucleolar RNA host genes (SNHGs) are a group of genes that can be transcript into long non-coding RNA SNHG (lncSNHG) and further processed into small nucleolar RNAs (snoRNAs). Although lncSNHGs and snoRNAs are well established to play pivotal roles in tumorigenesis, how lncSNHGs and snoRNAs regulate the immune cell behavior and function to mediate anti-tumor immunity remains further illustrated. Certain immune cell types carry out distinct roles to participate in each step of tumorigenesis. It is particularly important to understand how lncSNHGs and snoRNAs regulate the immune cell function to manipulate anti-tumor immunity. Here, we discuss the expression, mechanism of action, and potential clinical relevance of lncSNHGs and snoRNAs in regulating different types of immune cells that are closely related to anti-tumor immunity. By uncovering the changes and roles of lncSNHGs and snoRNAs in different immune cells, we aim to provide a better understanding of how the transcripts of SNHGs participate in tumorigenesis from an immune perspective.

show abstract

“…In recent years, with the development of sequencing technology, more and more data show that snoRNAs are dysregulated in many diseases including hematological malignancies, solid tumors, hereditary diseases, and metabolic diseases (Williams and Farzaneh, 2012); (Liu et al, 2020a); (Verbeek et al, 2022). In a study of snoRNAs from 33 patients with acute myeloid leukemia, the probability of snoRNA dysregulation was not high, with only 9.3% of C/D box snoRNAs and 0.9% of H/ACA box snoRNAs found to be significantly increased or decreased (including some putative novel snoRNAs, using a rigorous 5% false discovery rate).…”

Section: Snornasmentioning

confidence: 99%

The essential roles of small non-coding RNAs and RNA modifications in normal and malignant hematopoiesis

Cai

Wang

Han

et al. 2023

Front. Mol. Biosci.

View full text Add to dashboard Cite

Hematopoietic stem cells (HSCs) developing from mesoderm during embryogenesis are important for the blood circulatory system and immune system. Many factors such as genetic factors, chemical exposure, physical radiation, and viral infection, can lead to the dysfunction of HSCs. Hematological malignancies (involving leukemia, lymphoma, and myeloma) were diagnosed in more than 1.3 million people globally in 2021, taking up 7% of total newly-diagnosed cancer patients. Although many treatments like chemotherapy, bone marrow transplantation, and stem cell transplantation have been applied in clinical therapeutics, the average 5-year survival rate for leukemia, lymphoma, and myeloma is about 65%, 72%, and 54% respectively. Small non-coding RNAs play key roles in a variety of biological processes, including cell division and proliferation, immunological response and cell death. With the development of technologies in high-throughput sequencing and bioinformatic analysis, there is emerging research about modifications on small non-coding RNAs, as well as their functions in hematopoiesis and related diseases. In this study, we summarize the updated information of small non-coding RNAs and RNA modifications in normal and malignant hematopoiesis, which sheds lights into the future application of HSCs into the treatment of blood diseases.

show abstract

Dysregulation of Small Nucleolar RNAs in B-Cell Malignancies

Cited by 6 publications

References 119 publications

Small Nucleolar RNAs as Diagnostic and Prognostic Biomarkers in Cancer: A Systematic Review and Meta-Analysis

Small Nucleolar RNAs as Diagnostic and Prognostic Biomarkers in Cancer: A Systematic Review and Meta-Analysis

SnoRNA and lncSNHG: Advances of nucleolar small RNA host gene transcripts in anti-tumor immunity

The essential roles of small non-coding RNAs and RNA modifications in normal and malignant hematopoiesis

Contact Info

Product

Resources

About